| Today's Top Story |  |  | | - NIH unit sets aside $461M for genome sequencing project
The National Human Genome Research Institute has announced it will devote $461 million to projects that will help integrate DNA sequencing into mainstream medicine. A majority of the support, beginning at $86 million annually, will go to existing projects at three sequencing centers that were involved in the Human Genome Project. Some of the money will be used to establish projects dealing with the genetic basis of Mendelian illnesses and the effects of clinical sequencing. Nature (12/6)       - NIH offers $3M for tools to interpret sequencing data: The National Institute of General Medical Sciences will grant $3 million in 2013 for research involving biochemical, cellular, bioinformatic, statistical or high-throughput methods to interpret genomic sequencing data. GenomeWeb Daily News (12/2)
 | Earn 2X rewards points on shipping costs with The New Business Gold Rewards Card from American Express OPEN. Designed to earn Membership Rewards® points faster:
• 3X points on airfare
• 2X points on advertising, gas, and shipping
• 1X points on everything else
LEARN MORE AND APPLY |
  - Gates Foundation grants $37.2M for AIDS research
The Bill & Melinda Gates Foundation has agreed to give $37.2 million in grants to three HIV/AIDS researchers at Duke University. David Montefiori, who established the Comprehensive Antibody Vaccine Immune Monitoring Consortium, will receive $24.6 million over five years to continue moving preclinical vaccine discoveries into clinical trials. Dr. Baton Haynes and Dr. Michael Frank will receive three-year grants for $11.7 million and $892,000, respectively, for research on stimulating an immune response against HIV. MedCityNews.com (12/1) - Imaging method can help monitor nanotubes in cells, blood
U.S. researchers have developed an imaging method that can monitor carbon nanotubes in living cells and the bloodstream. The method, called transient absorption, employs pulsing near-infrared laser to give the nanotubes energy so that they can be imaged by a second near-infrared laser, according to the study published in Nature Nanotechnology. The method has potential applications in biomedical research and clinical medicine. BioOptics World (12/6) - Researchers offer integrated trial approach for personalized medicine
Researchers from the Fred Hutchinson Cancer Research Center in Seattle have proposed an integrated approach for conducting comparative clinical trials of personalized medicine technologies, including biomarker tests. The proposals, published in Health Affairs, include using established study groups for large-scale trials and distributing costs among public and private insurers. MolecularImaging.net (12/6) - "Health hackers" open access to genetic data
So-called health hackers or citizen scientists are making their personal genetic and health information public in an effort to bring medical research out from behind closed doors, they say. Some are running their own experiments and clinical trials. Companies have sprung up to further their efforts, and some medical journals have published their trial results. The Wall Street Journal (12/3) - Ebola vaccine is effective in mice, study shows
U.S. researchers reported that eight of 10 mice pretreated with PIC, an immune-boosting chemical, and a tobacco-based Ebola vaccine survived after being infected with the Ebola virus, while all mice that did not receive the shots died. The results imply that the vaccine is more stable than other Ebola vaccines, but more studies are needed to validate its efficacy in humans. Google/Agence France-Presse (12/6)  - Samsung and Biogen plan joint venture for follow-on biologics
Samsung and Biogen Idec agreed to form a $300 million joint venture in South Korea that will develop, produce and market generic versions of biotech drugs. Samsung will own 85% of the partnership, and the remaining 15% will be held by Biogen, in exchange for investing $45 million. The agreement "will allow us to leverage our world-class protein engineering and biologics manufacturing capabilities," Biogen CEO George Scangos said. The Boston Globe (tiered subscription model) (12/6)  | The Changing Role of Chemistry in Drug Discovery
This Thomson Reuters report delivers an in-depth review of the changing role of Chemistry and of Chemists in today's drug discovery research programs. With input from many key pharmaceutical industry players, supported with data from Thomson Reuters IntegritySM, it examines how life in drug discovery has changed and how it will continue to adapt in the future. Access the report here! |
 | Drug Development Basic Training | |  | | |  | - Sutro Biopharma's Hallam offers glimpse into future of drug design
BioPharm International talks to Dr. Trevor Hallam, chief scientific officer at Sutro Biopharma, a company that has developed a cell-free system for protein expression, about how Sutro positions itself in the market. Drug design approaches involving CHO- and other cell-based systems are discussed as are emerging therapeutic design areas that can be used for oncology and inflammation products. Hallam discusses the reiterative designs made possible by a cell-free system. Listen to the interview. | 
| Industrial & Environmental | | | | - House bill seeks to extend tariff on imported ethanol through 2014
Rep. Charles Rangel, D-N.Y., proposed legislation that would extend the 54-cent-per-gallon tariff on foreign ethanol through 2014. Under the Caribbean Basin Initiative, some Caribbean countries are allowed to sell a limited amount of dehydrated ethanol in the U.S. tax-free. If the import tariff is repealed, Brazilian ethanol would no longer need to undergo dehydration in the Caribbean, potentially destroying that region's refining industry, Rangel said. EthanolProducer.com (12/6) | News from BIO | | | | - Are you taking full advantage of your membership?
BIO's cost-savings program, BIO Business Solutions, is helping 2,700 companies nationwide save on the cost of essential products and services. Members of BIO and 43 state and regional biotech associations are eligible to receive preferential pricing and other benefits at no additional cost beyond their membership dues. VWR International, FedEx, Office Depot and Business Wire are just a few of the industry leading providers that offer special pricing through this members-only program. Learn more or enroll here.
| SmartQuote | | | |  | Ability will never catch up with the demand for it."
--Confucius,
Chinese philosopher  |
| | This SmartBrief was created for jmabs1@gmail.com
| | | Read more at SmartBrief.com | | A powerful website for SmartBrief readers including: | | | | | | | | | | Recent BIO SmartBrief Issues: - Tuesday, December 06, 2011
- Monday, December 05, 2011
- Friday, December 02, 2011
- Thursday, December 01, 2011
- Wednesday, November 30, 2011
| | | Lead Editor: Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004 | | | | | | © 1999-2011 SmartBrief, Inc.® Legal Information |
|
The 9th U.S. Circuit Court of Appeals said bone marrow donated through peripheral blood stem cell apheresis can be compensated because the procedure is akin to blood donation and not organ transplantation. The court, however, said bone marrow donated through a procedure called aspiration, which involves extracting bone marrow from a donor's bones, is still covered by the National Organ Transplant Act, which bans payments for bone marrow donations. 
No comments:
Post a Comment